Dianthus Therapeutics, Inc. /DE/

Developing selective antibody therapies for severe autoimmune diseases.

DNTH | NDAQ

Overview

Corporate Details

ISIN(s):: US2528281080 (+1 more)
LEI:
Country:: United States of America
Address:: 7 TIMES SQUARE, 10036 NEW YORK
Website:: https://dianthustx.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies for severe autoimmune diseases. The company focuses on designing and engineering potentially best-in-class monoclonal antibodies with improved potency, high selectivity, and extended half-lives. Its lead candidate, claseprubart (DNTH103), is an antibody that selectively targets the active C1s complement protein. The pipeline also includes DNTH212, a bifunctional inhibitor targeting Type 1 IFN suppression and B cell modulation. Dianthus's therapeutic approach aims to enable less frequent and more convenient self-administered subcutaneous injections, with the goal of improving clinical outcomes and quality of life for patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Dianthus Therapeutics, Inc. /DE/ filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Dianthus Therapeutics, Inc. /DE/

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Dianthus Therapeutics, Inc. /DE/ via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Bayer AG A life science firm providing pharmaceuticals, consumer health, and crop science solutions.	Germany	BAY
Beam Therapeutics Inc. Developing precision genetic medicines using base editing to provide cures for serious diseases.	United States of America	BEAM
BELITE BIO, INC Developing novel oral therapies for retinal degenerative eye diseases like GA and Stargardt disease.	United States of America	BLTE
Benchmark Holdings Plc Aquaculture biotech providing nutrition and health solutions for sustainable farming.	United Kingdom	BMK
Benitec Biopharma Inc. Develops ddRNAi gene therapies to silence genes causing chronic, life-threatening diseases.	United States of America	BNTC
BeOne Medicines Ltd. Develops innovative and accessible cancer treatments for patients worldwide.	United States of America	ONC
BGM Group Ltd. A pharma holding co. making APIs & TCM derivatives via bio-fermentation and extraction.	United States of America	BGM
Bicara Therapeutics Inc. Developing first-in-class, dual-action bifunctional therapies for solid tumor patients.	United States of America	BCAX
BICYCLE THERAPEUTICS PLC Developing novel bicyclic peptide medicines to precisely target hard-to-treat cancers.	United States of America	BCYC
BIFIDO. Co. Ltd Biotech firm specializing in microbiome R&D for functional foods and cosmeceuticals.	South Korea	238200